Published in Int J Oncol on September 19, 2017
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol (2009) 9.43
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
The Intestinal Wnt/TCF Signature. Gastroenterology (2006) 4.48
Development and evolution of the human neocortex. Cell (2011) 4.42
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 4.12
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol (2003) 3.53
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (2015) 3.48
The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol (2012) 3.16
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun (2014) 3.12
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 3.03
Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell (2004) 2.79
Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell (2015) 2.79
Cancer stem cells: the challenges ahead. Nat Cell Biol (2013) 2.78
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell (2012) 2.69
A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature (2017) 2.65
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature (2017) 2.54
Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat Rev Mol Cell Biol (2013) 2.51
Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol (2014) 2.49
Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal (2014) 2.42
Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol (2013) 2.35
The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood (2006) 2.33
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31
WNT/PCP signaling pathway and human cancer (review). Oncol Rep (2005) 2.17
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J (2007) 2.11
Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol (2015) 2.02
Planar cell polarity links axes of spatial dynamics in neural-tube closure. Cell (2012) 1.98
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell (2014) 1.98
Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res (2012) 1.89
Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol (2008) 1.82
K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell (2015) 1.80
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A (2012) 1.80
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A (2007) 1.77
A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res (2012) 1.70
ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One (2012) 1.69
The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell (2015) 1.66
FGF receptors: cancer biology and therapeutics. Med Res Rev (2013) 1.59
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med (2012) 1.54
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
The polycystin complex mediates Wnt/Ca(2+) signalling. Nat Cell Biol (2016) 1.49
The Basis of Oncoimmunology. Cell (2016) 1.47
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature (2017) 1.46
LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis (2013) 1.41
Non-equivalence of Wnt and R-spondin ligands during Lgr5(+) intestinal stem-cell self-renewal. Nature (2017) 1.41
Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy. Hypertension (2014) 1.40
Recurrent and functional regulatory mutations in breast cancer. Nature (2017) 1.39
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature (2017) 1.39
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res (2013) 1.38
YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol (2015) 1.29
The kinase TNIK is an essential activator of Wnt target genes. EMBO J (2009) 1.26
Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. Oncotarget (2015) 1.24
Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl (2015) 1.17
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest (2014) 1.16
Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene (2015) 1.11
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature (2017) 1.08
Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet (2017) 1.08
Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure. Nature (2015) 1.08
WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3. Br J Pharmacol (2014) 1.07
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget (2015) 1.07
Elements of cancer immunity and the cancer-immune set point. Nature (2017) 1.05
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A (2014) 1.04
Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov (2016) 1.02
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature (2015) 1.01
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med (2016) 1.01
Cloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family. Oncogene (1996) 1.01
WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT- beta-catenin-TCF signaling pathway. Biochem Biophys Res Commun (2001) 1.00
Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther (2014) 1.00
Wnt-Frizzled/Planar Cell Polarity Signaling: Cellular Orientation by Facing the Wind (Wnt). Annu Rev Cell Dev Biol (2015) 0.98
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov (2016) 0.98
Wnt signaling and the control of human stem cell fate. Stem Cell Rev (2014) 0.97
SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene (2013) 0.96
The Wnts of change: How Wnts regulate phenotype switching in melanoma. Biochim Biophys Acta (2015) 0.95
Wnt signaling in cancer. Oncogene (2016) 0.95
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res (2014) 0.93
Targeting the WNT Signaling Pathway in Cancer Therapeutics. Oncologist (2015) 0.92
The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest (2015) 0.91
Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling. Elife (2015) 0.90
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov (2017) 0.89
WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis. Oncotarget (2015) 0.89
Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res (2016) 0.88
AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Lett (2014) 0.88
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia (2014) 0.88
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov (2017) 0.87
Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. Cell Rep (2015) 0.87
Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling. Dev Cell (2016) 0.86
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med (2016) 0.85
Molecular genetics and targeted therapy of WNT-related human diseases (Review). Int J Mol Med (2017) 0.75